COV Share Price Performance
AU$0.36
0.02 (5.80%)
Price AU$0.36
Share PriceAU$0.36
Companies Like Cleo Diagnostics (ASX:COV) Are In A Position To Invest In Growth
Sep 10
Cleo Diagnostics Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
COV Community Narratives
There are no narratives available yet.
Recent COV News & Updates
Cleo Diagnostics Ltd Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.031
- Gross Margin
- 100.00%
- Net Profit Margin
- -473.17%
- Debt/Equity Ratio
- 0%
Cleo Diagnostics Ltd Competitors
Snowflake Analysis
About COV
- Founded
- 2021
- Employees
- n/a
- CEO
- WebsiteView website
Cleo Diagnostics Ltd, a biotechnology company, focuses on the development and commercializing of non-invasive blood tests to detect ovarian cancer in Australia. The company offers CleoDX pre-surgical triage tests which measures a combination of five biomarkers in serum to provide an accurate determination of malignancy risk prior to surgical referral. It also focuses on developing and testing intellectual property, testing the IP, and securing patents. Cleo Diagnostics Ltd was incorporated in 2021 and is based in Melbourne, Australia.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.3%
- 1 Year: 8.9%
- Year to Date: 9.5%
The market has stayed flat over the 7 days. As for the longer term, the market has risen 8.9% in the past 12 months. Earnings are forecast to grow by 11% annually. Market details ›